In a study with murine models, oncogenic Kras-targeted siRNA was loaded into mesenchymal stem cell-derived exosomes, which were then tested to confirm suppression of Kras in vitro and in vivo and a consequent increase in the survival of animals with pancreatic cancers [34]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.